Company intelligence / Profile preview
Lucina Biotherapeutics
Santa Cruz, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Lucina Biotherapeutics has published research in Science Translational Medicine showing that replenishing essential VLC-PUFAs can restore visual function in aged animals. Their lead program, LUC-101, targets dry AMD using a proprietary intravitreal formulation of C24:5n-3.
- Therapeutic areas
- OtherOphthalmology
- Modalities
- Lipid-based interventionsSynthetic biology
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Lucina Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lucina Biotherapeutics.